{"title":"医疗补助药物使用审查:一个关键的评估。","authors":"W J Moore","doi":"10.1177/107755879405100102","DOIUrl":null,"url":null,"abstract":"During the 1980s, prescription drug costs increased faster than other components of the Medicaid budget. In 1980, total vendor payments for prescription drugs were $1.3 billion, or 5.7 percent of all Medicaid expenditures. By 1990, prescription drug expenditures had risen to $4.4 billion, or 6.3 percent of the Medicaid budget (National Pharmaceutical Council 1991). Faced with this expenditure pattern and increasing federal deficits, Congress included a provision in the Omni-","PeriodicalId":79684,"journal":{"name":"Medical care review","volume":"51 1","pages":"3-37"},"PeriodicalIF":0.0000,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/107755879405100102","citationCount":"18","resultStr":"{\"title\":\"Medicaid drug utilization review: a critical appraisal.\",\"authors\":\"W J Moore\",\"doi\":\"10.1177/107755879405100102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"During the 1980s, prescription drug costs increased faster than other components of the Medicaid budget. In 1980, total vendor payments for prescription drugs were $1.3 billion, or 5.7 percent of all Medicaid expenditures. By 1990, prescription drug expenditures had risen to $4.4 billion, or 6.3 percent of the Medicaid budget (National Pharmaceutical Council 1991). Faced with this expenditure pattern and increasing federal deficits, Congress included a provision in the Omni-\",\"PeriodicalId\":79684,\"journal\":{\"name\":\"Medical care review\",\"volume\":\"51 1\",\"pages\":\"3-37\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/107755879405100102\",\"citationCount\":\"18\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical care review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/107755879405100102\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical care review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/107755879405100102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Medicaid drug utilization review: a critical appraisal.
During the 1980s, prescription drug costs increased faster than other components of the Medicaid budget. In 1980, total vendor payments for prescription drugs were $1.3 billion, or 5.7 percent of all Medicaid expenditures. By 1990, prescription drug expenditures had risen to $4.4 billion, or 6.3 percent of the Medicaid budget (National Pharmaceutical Council 1991). Faced with this expenditure pattern and increasing federal deficits, Congress included a provision in the Omni-